2 Canadian Pot Stocks Uplisted to the Nasdaq: Which Is a Better Buy?

Organigram Holdings Inc (TSXV:OGI) and The Flowr Corporation (TSXV:FLWR) have both uplisted to the Nasdaq, but which company provides the best buying opportunity?

| More on:

When comparing these two companies, the first thing to point out is that Organigram has much lower costs and higher production rates than Flowr. Organigram utilizes a three-tiered indoor grow system that enables the company to post industry-leading adjusted gross margins and the lowest cultivation costs in the country.

Organigram not only leads all Canadian cannabis producers with the lowest production costs, but it also recently received organic certification from Health Canada. This makes the company one of the largest producers of organic cannabis in Canada with an expected 113,000 kg of annual capacity by the end of 2019.

In comparison, Flowr has much higher costs and is banking on branding high-quality products that are expected to return much higher prices. FlowrRX, Flowr’s medical cannabis brand, is exclusively distributed by Shoppers Drug Mart and is the highest-priced cannabis sold by Shoppers.

Premium dried flower and derivatives

It may be the highest-priced cannabis on the market, but it is also more potent and of higher quality than most other products in Canada. Flowr argues, “high price is not what is driving consumers to the black market; poor quality is.”

Flowr is the only legal cannabis supplier in Canada that can produce dried flower that passes Health Canada testing “without the need for a decontamination ‘kill step.’”  Decontamination is a process where irradiation is used to reduce microbes to acceptable levels.

This makes the company stand out from the rest of the pack — something that helped Flowr gain an R&D partnership with one of the largest agricultural companies in North America: Scotts Miracle Gro.

Organigram may not be able to match the higher quality of Flowr, but it certainly has many advantages over its smaller competitor. Organigram is making large investments into CBD oils, edibles, and vaporizer technology.

In the fall of 2019, Organigram is expected to have an annual production of four million kgs of chocolate edibles and have invested $15 million into the project. The company is partnering with Canada’s Smartest Kitchen to assist in the production of cannabis-infused chocolate and to expand R&D into edibles.

When it comes to branding, both companies have made some interesting agreements. Flowr is working with the makers of Ace Hill Beer to develop Ace Valley, a luxury cannabis brand. Organigram has partnered with Canadian pop-culture icons the Trailer Park Boys to develop Trailer Park Bud.

Foolish bottom line

Both of these stocks have great potential. In the end, both of these companies will likely do very well. Flowr will likely dominate the premium high-grade market and has been working to reduce its production costs, which could put it over the top.

Organigram already has the lowest costs in the industry and is set to reach well over 100,000 kg of annual production in 2019. The company is set to burst into the edibles market in the fall of 2019 and is actively seeking beverage companies to partner with.

Overall, Flowr will do well catering to its niche market and may even be profitable, but it cannot match Organigram production or derivative sales. This could change if Holigen Global Health receives licensing to begin production in its Alentejo facility in Portugal.

Flowr owns 19.8% of Holigen, which is building the largest cannabis-cultivation facility in the world. Once licensed and fully operational, Alentejo will produce 635,000 kg of cannabis annually.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Michael Soares has no position in the companies mentioned.  

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »